These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 15274408)
1. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer. Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408 [TBL] [Abstract][Full Text] [Related]
2. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971 [TBL] [Abstract][Full Text] [Related]
3. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809 [TBL] [Abstract][Full Text] [Related]
4. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246 [TBL] [Abstract][Full Text] [Related]
5. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401 [TBL] [Abstract][Full Text] [Related]
6. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Wang CS; Wu TL; Tsao KC; Sun CF Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233 [TBL] [Abstract][Full Text] [Related]
7. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y Cancer Lett; 2000 Apr; 151(1):81-6. PubMed ID: 10766426 [TBL] [Abstract][Full Text] [Related]
9. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Zeng ZS; Cohen AM; Zhang ZF; Stetler-Stevenson W; Guillem JG Clin Cancer Res; 1995 Aug; 1(8):899-906. PubMed ID: 9816060 [TBL] [Abstract][Full Text] [Related]
10. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Holten-Andersen MN; Murphy G; Nielsen HJ; Pedersen AN; Christensen IJ; Høyer-Hansen G; Brünner N; Stephens RW Br J Cancer; 1999 May; 80(3-4):495-503. PubMed ID: 10408859 [TBL] [Abstract][Full Text] [Related]
11. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Ishida H; Murata N; Hayashi Y; Tada M; Hashimoto D Surg Today; 2003; 33(12):885-92. PubMed ID: 14669077 [TBL] [Abstract][Full Text] [Related]
12. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer. Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564 [TBL] [Abstract][Full Text] [Related]
13. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159 [TBL] [Abstract][Full Text] [Related]
14. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326 [TBL] [Abstract][Full Text] [Related]
15. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Frederiksen C; Lomholt AF; Davis GJ; Dowell BL; Blankenstein MA; Christensen IJ; Brünner N; Nielsen HJ Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer. Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001 [TBL] [Abstract][Full Text] [Related]
17. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030 [TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785 [TBL] [Abstract][Full Text] [Related]